Bayer's Pivotal Month: Legal and Financial Crossroads Converge

Bayer faces a pivotal Supreme Court hearing on Roundup litigation amid a €3.6B net loss and negative cash flow forecast. The outcome will shape its financial future.

The coming weeks represent one of the most critical periods in Bayer's recent history. The German conglomerate faces a convergence of high-stakes events: a staggering annual net loss, a concerning cash flow forecast, and a landmark hearing before the United States Supreme Court. The outcome, particularly of the legal proceedings, could define the company's trajectory for years.

Supreme Court Date Looms Large

The primary focus for investors is unequivocally legal. On April 27, the U.S. Supreme Court will hear Bayer’s appeal concerning a Roundup lawsuit verdict. The core legal question is whether federal law preempts state-level claims alleging failure to warn about cancer risks on the glyphosate-based herbicide's labeling.

A preliminarily approved settlement worth $7.25 billion is intended to resolve thousands of existing claims, with a payment structure spanning up to 21 years. However, CEO Bill Anderson has emphasized that claimant participation must reach nearly 100% for the framework to hold. An unfavorable ruling from the Supreme Court could render this settlement insufficient to permanently contain new litigation risk, leaving the company exposed.

Solid Operations Masked by Legal Overhang

Bayer’s 2025 annual results present a stark dichotomy. The company met its targets for group sales and adjusted EBITDA, reporting revenue of €45.6 billion and EBITDA before special items of €9.7 billion. Yet, the bottom line was plunged deep into negative territory by massive special provisions for ongoing litigation, resulting in a net loss of €3.6 billion.

The financial strain is projected to intensify. For 2026, Bayer anticipates spending approximately $5 billion on legal costs alone, which is expected to drive its free cash flow deeply negative, to an estimated minus €2.5 billion. The proposed dividend of €0.11 per share, to be voted on at the Annual Stockholders' Meeting on April 24, underscores the severely constrained financial flexibility.

Within this challenging context, the Crop Science division offered a glimmer of strength. Its Corn Seed business grew by 13.2%, bolstered by a licensing agreement with Corteva. This was partially offset by the loss of dicamba registration in the U.S., which significantly pressured soybean and cotton seed operations.

Share Price Reflects Profound Uncertainty

The stock market has priced in this high degree of uncertainty. After reaching a high of €49.17 in mid-February, Bayer shares have shed roughly 22% of their value. The current share price trades well below its 50-day moving average, while a Relative Strength Index (RSI) reading of 19.3 signals a severely oversold condition.

A Trifecta of Catalysts

Three key dates now cluster within a narrow timeframe, setting the stage for a directional shift: the Annual Meeting on April 24, the Supreme Court hearing on April 27, and the release of Q1 figures on May 12. A favorable decision from Washington could structurally defuse the litigation burden and pave the way for a fundamental re-rating of the stock. Conversely, an unfavorable or delayed ruling would likely mean the Roundup overhang will continue to weigh on the company for many years to come.